14.93

5.59% 0.79

After Hours: 14.78 -0.15 -1.00%

Neogenomics Inc (NEO)

Overview News Price History Option Chain Financials Why NEO Down? Discussions Forecast Stock Split

Neogenomics Inc stock is traded at $14.93, with a volume of 1.53M. It is up +5.59% in the last 24 hours and up +7.10% over the past month. NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.

Previous Close:

$14.14

Open:

$13.55

24h Volume:

1.53M

Relative Volume:

2.38

Market Cap:

$1.77B

Revenue:

$628.25M

Net Income/Loss:

$-78.55M

P/E Ratio:

-19.39

EPS:

-0.77

Net Cash Flow:

$-29.73M

1W Performance:

+10.43%

1M Performance:

+7.10%

6M Performance:

-2.42%

1Y Performance:

-2.23%

1-Day Range:

$13.35

$15.08

1-Week Range:

$13.21

$15.08

52-Week Range:

$12.77

$21.22

Neogenomics Inc Stock (NEO) Company Profile

Name

Neogenomics Inc

Sector

Healthcare (1182)

Industry

Diagnostics & Research (57)

Phone

(239) 768-0600

Address

9490 NEOGENOMICS WAY, FORT MYERS, FL

Employee

2,100

Twitter

@NeoGenomics

Next Earnings Date

2024-11-05

Latest SEC Filings

NEO's Discussions on Twitter

Neogenomics Inc Stock (NEO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-01-24	Resumed	Craig Hallum	Buy
Dec-29-23	Reiterated	BTIG Research	Buy
Aug-21-23	Upgrade	Stephens	Equal-Weight → Overweight
May-16-23	Downgrade	Raymond James	Outperform → Mkt Perform
May-09-23	Upgrade	BTIG Research	Neutral → Buy
Feb-24-23	Upgrade	The Benchmark Company	Hold → Buy
Feb-01-23	Upgrade	Needham	Hold → Buy
Aug-26-22	Downgrade	The Benchmark Company	Buy → Hold
Aug-22-22	Downgrade	Needham	Buy → Hold
Jun-03-22	Initiated	Piper Sandler	Overweight
Mar-29-22	Downgrade	BofA Securities	Buy → Neutral
Mar-29-22	Downgrade	Stephens	Overweight → Equal-Weight
Jan-18-22	Resumed	Stephens	Overweight
Dec-16-21	Initiated	Cowen	Outperform
Nov-05-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Oct-14-21	Upgrade	Raymond James	Mkt Perform → Outperform
Jun-03-21	Initiated	Goldman	Buy
Feb-25-21	Resumed	Needham	Buy
Feb-25-21	Downgrade	Raymond James	Outperform → Mkt Perform
Jan-28-21	Initiated	Truist	Buy
Dec-11-20	Resumed	BTIG Research	Buy
Oct-28-20	Reiterated	Needham	Buy
Sep-09-20	Initiated	Morgan Stanley	Overweight
Aug-28-20	Initiated	Guggenheim	Buy
Jul-29-20	Reiterated	Needham	Buy
Jun-25-20	Initiated	BofA/Merrill	Buy
Apr-21-20	Resumed	Stephens	Overweight
Mar-02-20	Resumed	Craig Hallum	Buy
Feb-28-20	Upgrade	First Analysis Sec	Outperform → Strong Buy
Jan-23-20	Downgrade	First Analysis Sec	Strong Buy → Outperform
Oct-30-19	Reiterated	Needham	Buy
May-01-19	Reiterated	Needham	Buy
Mar-29-19	Reiterated	Needham	Buy
Jan-03-19	Initiated	Needham	Buy
Oct-24-18	Upgrade	First Analysis Sec	Outperform → Strong Buy
Aug-21-18	Initiated	Leerink Partners	Outperform
May-02-18	Downgrade	First Analysis Sec	Overweight → Equal-Weight
Sep-11-17	Downgrade	BTIG Research	Buy → Neutral
Aug-24-17	Initiated	Gabelli & Co	Buy
Dec-15-16	Initiated	Cantor Fitzgerald	Overweight

View All

Neogenomics Inc Stock (NEO) Latest News

10:43 AM

NeoGenomics: Q3 Earnings Snapshot - The Washington Post

10:43 AM

10:00 AM

NeoGenomics (NEO) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance

10:00 AM

07:00 AM

NeoGenomics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

07:00 AM

05:42 AM

NeoGenomics, Inc. (NASDAQ:NEO) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

05:42 AM

Nov 03, 2024

Emerald Mutual Fund Advisers Trust Sells 314,330 Shares of NeoGenomics, Inc. (NASDAQ:NEO) - MarketBeat

Nov 03, 2024

Allspring Global Investments Holdings LLC Reduces Stake in NeoGenomics, Inc. (NASDAQ:NEO) - Defense World

Nov 03, 2024

Nov 02, 2024

Blue Trust Inc. Boosts Stake in NeoGenomics, Inc. (NASDAQ:NEO) - Defense World

Nov 02, 2024

Oct 29, 2024

NeoGenomics (NEO) to Release Earnings on Tuesday - MarketBeat

Oct 29, 2024

Oct 23, 2024

NeoGenomics gains conditional approval for solid tumour assays in New York - Medical Device Network

Oct 23, 2024

Oct 22, 2024

NeoGenomics NGS tests gain New York State approval - Investing.com

Oct 22, 2024

NEONeoGenomics, Inc. Latest Stock News & Market Updates - StockTitan

Oct 22, 2024

NeoGenomics Receives New York State Approval for Neo Comprehensive™ Solid Tumor Test - Business Wire

Oct 22, 2024

Oct 17, 2024

Truist Financial Corp Sells 4,699 Shares of NeoGenomics, Inc. (NASDAQ:NEO) - Defense World

Oct 17, 2024

Oct 16, 2024

NeoGenomics to Report Third Quarter 2024 Financial Results on Nov. 5, 2024 - BioSpace

Oct 15, 2024

Analytical Lens: Exploring Neogenomics Inc. (NEO)’s Financial Story Through Ratios - The Dwinnex

Oct 15, 2024

Oct 14, 2024

Check out these key findings about Neogenomics Inc. (NEO) - SETE News

Oct 14, 2024

Oct 13, 2024

Renaissance Technologies LLC Cuts Stock Holdings in NeoGenomics, Inc. (NASDAQ:NEO) - MarketBeat

Oct 13, 2024

Oct 12, 2024

(NEO) Technical Data - Stock Traders Daily

Oct 12, 2024

Oct 11, 2024

Breast Cancer Liquid Biopsy Market is expected to Double Its Size - openPR

Oct 11, 2024

NeoGenomics, Inc. (NASDAQ:NEO) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Oct 11, 2024

Oct 09, 2024

NEO (Neogenomics Inc.) may reap gains as insiders became active recently - Knox Daily

Oct 09, 2024